losartan-potassium has been researched along with cellulose-triacetate* in 3 studies
1 review(s) available for losartan-potassium and cellulose-triacetate
Article | Year |
---|---|
Vitamin B6 and hemodialysis: the impact of high-flux/high-efficiency dialysis and review of the literature.
High-flux/high-efficiency (HF/HE) dialysis is associated with improved clearance for larger molecules, which include a wide variety of middle molecules and water-soluble vitamins. Our study attempted to measure in vivo clearances of serum pyridoxal-5'-phosphate (PLP), the active metabolite of vitamin B6, on standard cuprophan versus cellulose triacetate HF/HE dialysis for patients maintained on 10 mg daily pyridoxine supplements. A longitudinal evaluation of PLP after 3 months on HF/HE dialysis was performed simultaneously. The average in vivo PLP clearance for six patients on standard hemodialysis increased by more than 50%, from 86 +/- 61.7 mL/min using a cuprophan membrane to 173 +/- 90.2 mL/min using a cellulose triacetate dialyzer, at average blood flows of 375 mL/min (P < 0.05). Levels of PLP decreased from a baseline of 50 +/- 13.8 ng/mL to 24 +/- 9.7 ng/mL (P < 0.05) after 3 months of HF/HE treatments; the levels returned to 45 +/- 6.4 ng/mL on resumption of standard dialysis treatments. Although not achieving statistical significance, the average hematocrit increased from 31.2% +/- 1.66% to 32.7% +/- 1.24% while on HF/HE dialysis without an increase in erythropoietin requirements. We conclude that HF/HE dialysis treatments can have a dramatic impact on vitamin B6 homeostasis. Further investigation to evaluate the effects of different membranes and reprocessing should be performed on more heterogeneous patient populations in whom compliance problems with diet and vitamin supplementation may exist. The increased clearance of vitamin B6 may have significantly more detrimental effects in these settings. Topics: Adult; Aged; Biocompatible Materials; Blood Flow Velocity; Cellulose; Diet; Erythropoietin; Female; Hematocrit; Homeostasis; Humans; Longitudinal Studies; Male; Membranes, Artificial; Middle Aged; Patient Compliance; Pyridoxal Phosphate; Pyridoxine; Renal Dialysis | 1996 |
1 trial(s) available for losartan-potassium and cellulose-triacetate
Article | Year |
---|---|
A randomized, controlled study of the consequences of hemodialysis membrane composition on erythropoietic response.
Membrane biocompatibility has long been thought to be relevant to hemodialysis outcomes and, possibly, renal anemia.. We performed a randomized, controlled, single-center study comparing the consequences on renal anemia of 2 dialyzers of equivalent performance, but different composition, during 7 months. Two hundred eleven patients of an unselected dialysis population of 235 patients gave informed consent to undergo random assignment to either group A (SF170E; modified cellulose triacetate/midflux membrane; Nipro, Osaka, Japan) or group B (HF80LS; polysulfone/high-flux membrane; Fresenius, Bad Homburg, Germany). Anemia management was identical in both treatment groups and followed strict clinical protocols managed by computer algorithms. Dialysis adequacy, hemoglobin (Hb) level, ferritin level, percentage of red blood cell hypochromicity, C-reactive protein (CRP) level, and intravenous iron and epoetin doses were monitored monthly.. One hundred seventy-seven patients completed the 7-month study. Equilibrated Kt/V increased in both groups. Hb outcome improved overall, but did not differ between the 2 study groups. Epoetin dose was not significantly different after 7 months compared with baseline in either group. Hb level, epoetin dose, iron status, CRP level, dialysis Kt/V, and residual renal function did not differ between the 2 groups. A slight but significant negative correlation was identified between dialysis Kt/V and Hb level in the population as a whole (Spearman's correlation, -0.16; P = 0.04).. No significant epoetin-sparing effect was identified through the use of the high-flux polysulfone HF80LS membrane over the modified cellulose triacetate SF170E membrane. Although not a primary outcome for this study, there was a suggestion of benefit of improved Hb level, without increased need for epoetin, through increasing delivered dialysis dose. Topics: Adult; Aged; Anemia; C-Reactive Protein; Cellulose; Epoetin Alfa; Erythrocytes; Erythropoietin; Female; Ferritins; Hemoglobins; Humans; Iron; Kidney Failure, Chronic; Male; Membranes, Artificial; Middle Aged; Parathyroid Hormone; Phosphorus; Polymers; Potassium; Recombinant Proteins; Renal Dialysis; Sulfones | 2003 |
1 other study(ies) available for losartan-potassium and cellulose-triacetate
Article | Year |
---|---|
[Erythropoietin].
Topics: Acrylic Resins; Adsorption; beta 2-Microglobulin; Cellulose; Erythropoietin; Humans; Membranes, Artificial; Polymers; Recombinant Proteins; Renal Dialysis; Sulfones | 1991 |